Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, 15-276, Bialystok, Poland.
Present address: Clinical Research Centre, Medical University of Bialystok, 15-276, Bialystok, Poland.
BMC Cancer. 2019 Apr 29;19(1):398. doi: 10.1186/s12885-019-5558-8.
The search of useful serum biomarkers for the early detection of cervical cancers has been of a high priority. The activation of Macrophage-Colony Stimulating Factor (M-CSF) and Vascular Endothelial Growth Factor (VEGF) is likely involved in the pathogenesis and spread of cancer. We compared the plasma levels of M-CSF and VEGF to the ones of commonly accepted tumor markers CA 125and SCC-Ag in three groups of patients: 1. the cervical cancer group (patients with either squamous cell carcinoma or adenocarcinoma); 2. the cervical dysplasia group; 3. the control group.
This cohort study included 100 patients with cervical cancer and 55 patients with cervical dysplasia. The control group consisted of 50 healthy volunteers. The plasma levels of VEGF and M-CSF were determined using ELISA, while CA 125 and SCC-Ag concentrations were obtained by the chemiluminescent microparticle immunoassay (CMIA).
The median levels of M-CSF and VEGF as well as CA 125 and SCC-Ag in the entire group of cervical cancer patients, were significantly different compared to the healthy women group. In case of both the squamous cell carcinoma and the adenocarcinoma groups, plasma levels of M-CSF and VEGF were higher compared to the control group. No significant differences in the studied parameters between the squamous cell carcinoma and the adenocarcinoma group were observed. The highest sensitivity and specificity were obtained for VEGF (81.18 and 76.00%, respectively) and SCC-Ag (81.18%; 74.00%) in the squamous cell carcinoma group and for VEGF (86.67%; 76.00%) in the adenocarcinoma group. The area under the ROC curve for VEGF was the largest in the adenocarcinoma group followed by the squamous cell carcinoma group (0.9082 and 0.8566 respectively).
Obtained results indicate a possible clinical applicability and a high diagnostic power for the combination of MSC-F, VEGF, CA 125 and SCC-Ag in the diagnosis of both studied types of cervical cancer.
寻找有用的血清生物标志物来早期检测宫颈癌一直是当务之急。巨噬细胞集落刺激因子（M-CSF）和血管内皮生长因子（VEGF）的激活可能参与了癌症的发病机制和扩散。我们比较了三组患者的血浆 M-CSF 和 VEGF 水平与常用肿瘤标志物 CA 125 和 SCC-Ag 的水平：1. 宫颈癌组（鳞癌或腺癌患者）；2. 宫颈发育不良组；3. 对照组。
这项队列研究包括 100 名宫颈癌患者和 55 名宫颈发育不良患者。对照组由 50 名健康志愿者组成。使用 ELISA 测定 VEGF 和 M-CSF 的血浆水平，而 CA 125 和 SCC-Ag 浓度则通过化学发光微粒子免疫分析（CMIA）获得。
整个宫颈癌患者组的 M-CSF 和 VEGF 中位数水平以及 CA 125 和 SCC-Ag 浓度与健康女性组相比有显著差异。在鳞癌组和腺癌组中，M-CSF 和 VEGF 的血浆水平均高于对照组。在鳞癌和腺癌组之间，研究参数没有显著差异。在鳞癌组中，VEGF（81.18%和 76.00%）和 SCC-Ag（81.18%；74.00%）获得了最高的敏感性和特异性，而在腺癌组中，VEGF（86.67%；76.00%）获得了最高的特异性。VEGF 的 ROC 曲线下面积在腺癌组最大，其次是鳞癌组（分别为 0.9082 和 0.8566）。
研究结果表明，M-CSF、VEGF、CA 125 和 SCC-Ag 的组合在诊断两种类型的宫颈癌方面具有潜在的临床应用价值和较高的诊断能力。
